Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy.
Richiardone E, Al Roumi R, Lardinois F, Giolito MV, Ambroise J, Boidot R, Drotleff B, Ghesquière B, Bellahcène A, Bardelli A, Arena S, Corbet C. Richiardone E, et al. Among authors: bardelli a. Cancer Lett. 2024 Aug 28;598:217091. doi: 10.1016/j.canlet.2024.217091. Epub 2024 Jul 2. Cancer Lett. 2024. PMID: 38964730 Free article.
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M, Dell'Omo G, Grassi E, Mariella E, Leto SM, Scardellato S, Lorenzato A, Arena S, Bertotti A, Trusolino L, Bardelli A, d'Adda di Fagagna F. Falcinelli M, et al. Among authors: bardelli a. Cell Death Dis. 2023 Feb 9;14(2):96. doi: 10.1038/s41419-023-05640-3. Cell Death Dis. 2023. PMID: 36759506 Free PMC article.
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.
Torchiaro E, Petti C, Arena S, Sassi F, Migliardi G, Mellano A, Porporato R, Basiricò M, Gammaitoni L, Berrino E, Montone M, Corti G, Crisafulli G, Marchiò C, Bardelli A, Medico E. Torchiaro E, et al. Among authors: bardelli a. Front Oncol. 2023 Feb 2;13:1130852. doi: 10.3389/fonc.2023.1130852. eCollection 2023. Front Oncol. 2023. PMID: 36816936 Free PMC article.
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Sogari A, Rovera E, Grasso G, Mariella E, Reilly NM, Lamba S, Mauri G, Durinikova E, Vitiello PP, Lorenzato A, Avolio M, Piumatti E, Bonoldi E, Aquilano MC, Arena S, Sartore-Bianchi A, Siena S, Trusolino L, Donalisio M, Russo M, Di Nicolantonio F, Lembo D, Bardelli A. Sogari A, et al. Among authors: bardelli a. Cell Rep Med. 2024 Feb 20;5(2):101376. doi: 10.1016/j.xcrm.2023.101376. Epub 2024 Jan 15. Cell Rep Med. 2024. PMID: 38228147 Free PMC article.
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.
Corti G, Buzo K, Berrino E, Miotto M, Aquilano MC, Lentini M, Bellomo SE, Lorenzato A, Bartolini A, Mauri G, Lazzari L, Russo M, Di Nicolantonio F, Siena S, Marsoni S, Marchiò C, Bardelli A, Arena S. Corti G, et al. Among authors: bardelli a. NPJ Precis Oncol. 2024 Oct 14;8(1):231. doi: 10.1038/s41698-024-00706-7. NPJ Precis Oncol. 2024. PMID: 39402170 Free PMC article.
Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S, Sartore-Bianchi A. Mauri G, et al. Among authors: bardelli a. Front Oncol. 2022 Nov 7;12:1030232. doi: 10.3389/fonc.2022.1030232. eCollection 2022. Front Oncol. 2022. PMID: 36419886 Free PMC article.
Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S, Sartore-Bianchi A. Mauri G, et al. Among authors: bardelli a. Front Oncol. 2023 Mar 28;13:1147497. doi: 10.3389/fonc.2023.1147497. eCollection 2023. Front Oncol. 2023. PMID: 37056342 Free PMC article.
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G, Napolitano S, Famiglietti V, Del Tufo S, Masi G, Santini D, Avallone A, Pietrantonio F, Lonardi S, Di Maio M, Zampino MG, Fazio N, Bardelli A, Siena S, Cremolini C, Sartore-Bianchi A, Ciardiello F. Ciardiello D, et al. Among authors: bardelli a. JAMA Netw Open. 2024 Apr 1;7(4):e245635. doi: 10.1001/jamanetworkopen.2024.5635. JAMA Netw Open. 2024. PMID: 38592721 Free PMC article. Clinical Trial.
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V, Lamba S, Chilà R, Cattaneo CM, Mussolin B, Corti G, Rospo G, Berrino E, Tripodo C, Pisati F, Bartolini A, Aquilano MC, Marsoni S, Mauri G, Marchiò C, Abrignani S, Di Nicolantonio F, Germano G, Bardelli A. Amodio V, et al. Among authors: bardelli a. Cancer Cell. 2023 Jan 9;41(1):196-209.e5. doi: 10.1016/j.ccell.2022.12.003. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584674 Free PMC article.
368 results